Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to…
ImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer Center ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the execution of a Memorandum of…
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially…
Innovate 32 Partners with Crestview Dental and Cedar Street Family Dentistry, Continuing Momentum in East Tennessee Innovate 32 a growth-oriented dental services organization, today announced new partnerships with Crestview Dental and Cedar Street Family Dentistry, two highly respected general dentistry…
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the…
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema…
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…
Kivu Bioscience Names Brunilda Shtylla as Chief Business Officer to Lead Strategic Growth and Partnership Initiatives Kivu Bioscience, a clinical-stage biotechnology company dedicated to advancing next-generation antibody-drug conjugates (ADCs) for the treatment of difficult-to-treat cancers, has announced the appointment of…
Intellia Therapeutics Reports FDA Clearance to Resume MAGNITUDE Phase 3 Study in ATTR-CM Following Removal of Clinical Hold Intellia Therapeutics has cleared a significant regulatory hurdle in its effort to advance CRISPR-based gene editing into late-stage cardiovascular medicine, announcing that…
AbbVie Reports Positive Phase 3 Results for Subcutaneous SKYRIZI® in Crohn’s Disease AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous (SC) induction…
Pivotal Study Shows Significant Improvements in Hematocrit Control and Patient Outcomes What does the future hold for patients with polycythemia vera (PV)? Takeda and Protagonist Therapeutics, Inc. have announced a significant milestone in the treatment of this rare blood disorder.…
Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc. a pioneer in cord blood and cord tissue cryopreservation, has…